GSK plc reports

Company location
London
GSK plc has filed 6,789 SEC EDGAR filings since 12 Jan 2001

SEC filing history

Showing 901-925 of 1,000 matching filings.

Per page
25
Current page
37
6-K File 001-15170

MENVEO NEW SINGLE-VIAL APPROVED BY US FDA

Filing date
17 Oct 2022
Reporting date
17 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
14 Oct 2022
Reporting date
14 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Oct 2022
Reporting date
13 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Oct 2022
Reporting date
13 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Oct 2022
Reporting date
13 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

EFFICACY RESULTS FOR GSK'S OLDER ADULT RSV VACCINE

Filing date
13 Oct 2022
Reporting date
13 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
12 Oct 2022
Reporting date
12 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

US FDA APPROVES BOOSTRIX MATERNAL IMMUNISATION

Filing date
11 Oct 2022
Reporting date
11 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
07 Oct 2022
Reporting date
07 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
07 Oct 2022
Reporting date
07 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
03 Oct 2022
Reporting date
03 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
30 Sep 2022
Reporting date
30 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
26 Sep 2022
Reporting date
26 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK CHIEF FINANCIAL OFFICER SUCCESSION

Filing date
26 Sep 2022
Reporting date
26 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

US FDA ODAC REVIEW OF ZEJULA PHASE III NOVA TRIAL

Filing date
22 Sep 2022
Reporting date
22 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK AND SPERO THERAPEUTICS LICENCE FOR TEBIPENEM

Filing date
22 Sep 2022
Reporting date
22 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
21 Sep 2022
Reporting date
21 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-36033

4 filing

Filing date
20 Sep 2022
Reporting date
16 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A

AMENDMENT TO FORM SC 13D

Filing date
20 Sep 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-15170

25-NSE filing

Filing date
15 Sep 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Sep 2022
Reporting date
13 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
08 Sep 2022
Reporting date
08 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK PROVIDES UPDATE ON FDA REVIEW OF DAPRODUSTAT

Filing date
06 Sep 2022
Reporting date
06 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-15170

25-NSE filing

Filing date
01 Sep 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
01 Sep 2022
Reporting date
01 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .